This case illustrates the importance of performing abdominal ultrasound to monitor the size of the abdominal aorta, in particular after the second trimester of gestation when cardiac output increases. When any increase in the size of the aorta is documented on abdominal ultrasound, magnetic resonance is indicated to achieve a more precise assessment. The risk of aortic rupture or dissection secondary to development of a large dilatation or aneurysm is very high and implies a dismal prognosis.

All women with Marfan syndrome who wish to have a baby should be evaluated and counseled by a multidisciplinary team, primarily a cardiologist and obstetrician, with individualized determination of the associated risk.

María Goya,a,b Maria Alvarez,b Gisela Teixido-Tura,b Carme Merced,b Víctor Pineda,b and Arturo Evangelistab

aUnidad de Medicina Materno-Fetal, Servicio de Obstetricia, Hospital Universitari Vall d’Hebron, Barcelona, Spain
bUnidad de Marfan, Servicio de Cardiología, Hospital Universitari Vall d’Hebron, Barcelona, Spain

P Wave Morphology and Recurrence After Cardioversion of Lone Atrial Fibrillation

Morfología de la onda P y recurrencia tras cardioversión de fibrilación auricular aislada

To the Editor,

Approximately 30%-60% of patients who undergo cardioversion for atrial fibrillation (AF) suffer a recurrence (R-AF) in the midterm. Among the different variables associated with R-AF, dilation of the left atrium (LA) is probably among the best known. Little information exists, however, on the capacity of the morphology of the P wave to predict the probability of R-AF. The P wave reflects the electrical depolarization of the atrium. When it is biphasic in the precordial V1 lead, the negative terminal portion represents the electrical activation of the LA. An increase in its magnitude is associated with an increase in the volume of the LA, a delay in conduction, or both. We aimed to determine whether the presence of a negative terminal deflection of the P wave in V1 of ≥0.1 mV and lasting ≥40 ms (NTDV1) distinguishes patients at greater risk of R-AF following cardioversion for lone AF of recent onset (Fig. 1).

Between January 2006 and March 2007, we undertook a prospective study of 146 consecutive patients with lone AF of recent onset (<48 h) that was reverted to sinus rhythm (SR) at our center: in 61 patients (42%) the AF episode ended spontaneously; 85 patients (58%) required either electrical (n = 38) or pharmacological cardioversion (n = 47). No patient suffered ventricular dysfunction nor any significant valve disease. Table 1 shows the baseline characteristics of the patient population. Follow-up was undertaken for one year. R-AF was defined as a clinical recurrence (the perception of an arrhythmic pulse lasting more than 1 min) or an electrocardiographic recurrence detected during programmed or additional appointments during follow-up.

All calculations were performed using SPSS/PC v.17 software (SPSS Inc.; Chicago, Illinois, United States). Continuous variables

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value for the entire sample, no. (%)</th>
<th>R-AF (%)α</th>
<th>Log rank (χ²)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;75 years</td>
<td>40 (27)</td>
<td>40 vs 56</td>
<td>0.43</td>
<td>.51</td>
</tr>
<tr>
<td>Men</td>
<td>93 (53)</td>
<td>56 vs 59</td>
<td>0.11</td>
<td>.74</td>
</tr>
<tr>
<td>High blood pressure</td>
<td>90 (61)</td>
<td>57 vs 57</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>21 (14)</td>
<td>52 vs 58</td>
<td>0.62</td>
<td>.43</td>
</tr>
<tr>
<td>Persistent AF</td>
<td>85 (58)</td>
<td>59 vs 56</td>
<td>1.16</td>
<td>.28</td>
</tr>
<tr>
<td>Treatment with anti-arrhythmia medication</td>
<td>56 (38)</td>
<td>50 vs 62</td>
<td>1.51</td>
<td>.22</td>
</tr>
<tr>
<td>ACEI/ARB-II</td>
<td>77 (53)</td>
<td>55 vs 61</td>
<td>1.54</td>
<td>.22</td>
</tr>
<tr>
<td>Creatinine clearance &lt;60 ml/min</td>
<td>18 (12)</td>
<td>78 vs 55</td>
<td>6.92</td>
<td>.01</td>
</tr>
<tr>
<td>Area of LA ≥20 cm²</td>
<td>85 (54)</td>
<td>65 vs 48</td>
<td>6.8</td>
<td>.01</td>
</tr>
<tr>
<td>NTDV1</td>
<td>65 (44)</td>
<td>72 vs 46</td>
<td>11.55</td>
<td>.001</td>
</tr>
</tbody>
</table>

ACEI, angiotensin converting enzyme inhibitors; AF, atrial fibrillation; ARB-II, angiotensin II AT1 receptor antagonists; LA, left atrium; NTDV1, negative terminal deflection of the P wave in V1 of ≥0.1 mV lasting ≥40 ms; R-AF, recurrent atrial fibrillation.

α Percentage of patients with recurrent AF after cardioversion (present vs absent).

β Twenty-eight patients were treated with amiodarone and 28 with flecainide.

REFERENCES


doi: 10.1016/j.rec.2011.04.023
with a normal distribution were described as means ± standard deviation; continuous variables not showing a normal distribution were expressed as medians [interquartile range]; categorical variables were expressed as absolute numbers and percentages. These different groups of variables were analyzed using the Student t test, the Mann-Whitney U test and the \( \chi^2 \) test respectively. The log rank method was used for the univariate analysis of survival. The independent predictors of R-AF during follow-up were determined via Cox regression analysis including the following variables: age >75 years, male sex, high blood pressure, diabetes mellitus, persistent AF, treatment with type II or III anti-arrhythmia drugs (AAD), angiotensin converting enzyme inhibitors/angiotensin II receptor AT1 antagonists, creatinine clearance <60 ml/min, area of the LA in apical four chamber plane (cm²), and NTDV1. Significance was set at \( P < .05 \).

After 1 year of follow-up, 84 patients (58%) suffered R-AF. Table 1 shows the relationship between the different variables and the frequency of R-AF. Sixty-five (46%) patients showed NTDV1 after the recovery of SR, although this was significantly more prevalent in patients with persistent AF (52% compared to 34%; \( P = .044 \)). R-AF was more common in patients with NTDV1 (73% compared to 46%; \( P = .001 \)) (Fig. 1). Cox regression analysis showed the independent predictors of R-AF to be: NTDV1 (odds ratio \( \text{OR} = 1.9; \ P = .007 \), LA area (\( \text{OR} = 1.1; \ P < .001 \)) and treatment with AAD (\( \text{OR} = 0.52; \ P = .013 \)). NTDV1 was associated with a greater incidence of R-AF in patients with a non-dilated LA (64% compared to 39%; non-adjusted \( P = .02 \)) and in those with an LA area of >20 cm² (77% compared to 53%; non-adjusted \( P = .04 \)).

This study shows that, in patients with no structural heart disease, the presence of NTDV1 is independently associated with an increase in the risk of R-AF in the first year following cardioversion to recover SR. The slowing down of electrical conduction, the pressure and/or volume overload of the LA, and structural changes (such as dilation or hypertrophy) all increase the magnitude of the terminal deflection of the P wave in V1.\(^5\)\(^6\) These factors have all been related to the development of changes in the histological and electrophysiological characteristics of the LA\(^5\) and may therefore favor R-AF after the recovery of SR. It is assumed that in patients with AF, electrical abnormalities precede anatomical changes. Although we observed that NTDV1 was more common among patients with a dilated LA, the association between NTDV1 and R-AF was independent of the size of the atrium. This might indicate that this association defines a relatively early delay in atrial conduction, earlier sometimes than the dilation of the LA.

Given the type of follow-up pursued, in which long periods elapsed without electrocardiographic monitoring, R-AF might have been underestimated since many recurrences are asymptomatic. Finally, neither the duration of episodes nor the prior arrhythmic load were included in the statistical analysis (although in all patients AF lasted less than 48 h). Their inclusion may have provided extra information.

Ana Martín García, Javier Jiménez-Candil, Jesús Hernández, Agustín Martín García, Francisco Martín Herrero, and Cándido Martín Luengo

Servicio de Cardiología, Hospital Universitario, Salamanca, Spain

*Corresponding author:

E-mail address: jimenezcandil@secardiologia.es
(J. Jiménez-Candil).

Available online 30 July 2011

REFERENCES
